SECTOR
Biocon’s arm signs settlement and license agreement with Regeneron, Bayer
Dec-13-2025

Biocon’s subsidiary -- Biocon Biologics has signed new settlement and license agreement with Regeneron and Bayer for biosimilar Aflibercept (40mg/ml) in Europe and the rest of the world, which follows an earlier settlement covering the United States and Canada.

This agreement clears the way for Biocon Biologics to commercialize Yesafili, a biosimilar Aflibercept (40mg/ml), in all countries worldwide. Yesafili is a vascular endothelial growth factor (VEGF) inhibitor used to treat multiple ophthalmology conditions.

Biocon Biologics, Regeneron and Bayer executed the agreement to dismiss all pending litigation. This agreement enables the company to launch Yesafili in the United Kingdom in January 2026 and in the rest of the settled countries in March 2026 or earlier in certain circumstances. 

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


  RELATED NEWS >>